Non-invasive Visualisation of the Development of Peritoneal Carcinomatosis and Tumour Regression After 213Bi-radioimmunotherapy Using Bioluminescence Imaging
Purpose Non-invasive imaging of tumour development remains a challenge, especially for tumours in the intraperitoneal cavity. Therefore, the aim of this study was the visualisation of both the development of peritoneal carcinomatosis and tumour regression after radioimmunotherapy with tumour-specific 213Bi-Immunoconjugates, via in vivo bioluminescence imaging of firefly luciferase-transfected cells.
Methods Human diffuse-type gastric cancer cells expressing mutant d9-E-cadherin were stably transfected with firefly luciferase (HSC45-M2-luc). For bioluminescence imaging, nude mice were inoculated intraperitoneally with 1 × 107 HSC45-M2-luc cells. On days 4 and 8 after tumour cell inoculation, imaging was performed following D-luciferin injection using a cooled CCD camera with an image intensifier unit. For therapy, mice were injected with 2.7 MBq 213Bi-d9MAb targeting d9-E-cadherin on day 8 after tumour cell inoculation. Bioluminescence images were taken every 4 days to monitor tumour development.
BUCHHORN H.M.;
SEIDL C.;
BECK R.;
SAUR D.;
APOSTOLIDIS Christos;
MORGENSTERN Alfred;
SCHWAIGER M.;
SENEKOWITSCH-SCHMIDTKE R.;
2007-08-09
Springer Verlag
JRC38135
https://publications.jrc.ec.europa.eu/repository/handle/JRC38135,
10.1007/s00259-006-0311-3,
Additional supporting files
| File name | Description | File type | |
|---|
